EA199700364A1 - Способ контроля силилирования протеинов, продуцируемых в культуре клеток млекопитающих - Google Patents
Способ контроля силилирования протеинов, продуцируемых в культуре клеток млекопитающихInfo
- Publication number
- EA199700364A1 EA199700364A1 EA199700364A EA199700364A EA199700364A1 EA 199700364 A1 EA199700364 A1 EA 199700364A1 EA 199700364 A EA199700364 A EA 199700364A EA 199700364 A EA199700364 A EA 199700364A EA 199700364 A1 EA199700364 A1 EA 199700364A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- cell culture
- sialic acid
- methods
- culture
- sililation
- Prior art date
Links
- 210000004962 mammalian cell Anatomy 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 102000004169 proteins and genes Human genes 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
- 238000004113 cell culture Methods 0.000 abstract 6
- 102000003886 Glycoproteins Human genes 0.000 abstract 3
- 108090000288 Glycoproteins Proteins 0.000 abstract 3
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 abstract 2
- 208000027866 inflammatory disease Diseases 0.000 abstract 2
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 abstract 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 abstract 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 239000003623 enhancer Substances 0.000 abstract 1
- 210000000987 immune system Anatomy 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000002547 new drug Substances 0.000 abstract 1
- 238000013518 transcription Methods 0.000 abstract 1
- 230000035897 transcription Effects 0.000 abstract 1
- 230000014616 translation Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/005—Glycopeptides, glycoproteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0018—Culture media for cell or tissue culture
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/36—Lipids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/60—Buffer, e.g. pH regulation, osmotic pressure
Abstract
В заявке описан новый способ получения гликопротеинов с помощью культуры клеток млекопитающего, в котором содержание сиаловой кислоты в продуцируемом гликопротеине контролируют в широком диапазоне значений, варьируя среду для культивирования клеток. Изобретение относится к способам, в которых содержание сиаловой кислоты в гликопротеине модифицируют, изменяя параметры культивирования клеток, оказывающие воздействие на удельную продуктивность клеток. Предпочтительные варианты осуществления изобретения включают способы культивирования клеток, в которых во время фазы продуцирования протеина культурой клеток контролируют осмоляльность клеточной культуры, а также концентрацию энхансера транскрипции. Кроме того, изобретение относится к новым препаратам, включающим растворимый фактор некроза опухоли типа 1-иммуноглубулин G, и к их применению для лечения воспалительных заболеваний или расстройств, связанных с иммунной системой.Международная заявка была опубликована вместе с отчетом о международном поиске.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/469,348 US5705364A (en) | 1995-06-06 | 1995-06-06 | Mammalian cell culture process |
PCT/US1996/009284 WO1996039488A1 (en) | 1995-06-06 | 1996-06-06 | Process for controlling sialylation of proteins produced by mammalian cell culture |
Publications (2)
Publication Number | Publication Date |
---|---|
EA199700364A1 true EA199700364A1 (ru) | 1998-04-30 |
EA001215B1 EA001215B1 (ru) | 2000-12-25 |
Family
ID=23863440
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA199700364A EA001215B1 (ru) | 1995-06-06 | 1996-06-06 | Способ контроля количества сиаловой кислоты, присутствующей в олигосахаридной боковой цепи гликопротеина, способ получения химерного гликопротеина, препарат, содержащий химерный гликопротеин, и терапевтическая композиция |
Country Status (36)
Country | Link |
---|---|
US (1) | US5705364A (ru) |
EP (2) | EP1609853B2 (ru) |
JP (2) | JPH11507523A (ru) |
KR (1) | KR100496356B1 (ru) |
CN (1) | CN1166772C (ru) |
AR (2) | AR004940A1 (ru) |
AT (2) | ATE302266T1 (ru) |
AU (1) | AU717847B2 (ru) |
BG (1) | BG63213B1 (ru) |
BR (1) | BR9609150A (ru) |
CA (1) | CA2220684C (ru) |
CZ (1) | CZ293719B6 (ru) |
DE (2) | DE69637867D1 (ru) |
DK (2) | DK1609853T4 (ru) |
EA (1) | EA001215B1 (ru) |
ES (2) | ES2248812T5 (ru) |
GE (1) | GEP20012519B (ru) |
HK (2) | HK1017903A1 (ru) |
HU (1) | HU226420B1 (ru) |
IL (1) | IL122398A (ru) |
IS (1) | IS2614B (ru) |
MY (1) | MY113496A (ru) |
NO (1) | NO322276B1 (ru) |
NZ (1) | NZ310202A (ru) |
OA (1) | OA10753A (ru) |
PL (1) | PL185484B1 (ru) |
PT (1) | PT1609853E (ru) |
RO (1) | RO120267B1 (ru) |
SA (1) | SA96170351B1 (ru) |
SI (2) | SI0832189T2 (ru) |
SK (1) | SK282658B6 (ru) |
TR (1) | TR199701543T1 (ru) |
TW (2) | TW426734B (ru) |
UA (1) | UA47428C2 (ru) |
WO (1) | WO1996039488A1 (ru) |
ZA (1) | ZA964776B (ru) |
Families Citing this family (113)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK0939121T4 (da) | 1989-09-12 | 2008-02-04 | Ahp Mfg B V | TNF-bindende proteiner |
US6656466B1 (en) * | 1995-06-06 | 2003-12-02 | Genetech, Inc. | Human tumor necrosis factor—immunoglobulin(TNFR1-IgG1) chimera composition |
US5705364A (en) † | 1995-06-06 | 1998-01-06 | Genentech, Inc. | Mammalian cell culture process |
JP4306813B2 (ja) | 1995-09-19 | 2009-08-05 | アスビオファーマ株式会社 | 動物細胞の新規培養方法 |
CA2253557A1 (en) * | 1996-05-08 | 1997-11-13 | Louis Martin Renzetti | Treatment of asthma with tnfr-ig |
US6673575B1 (en) * | 1997-12-03 | 2004-01-06 | Roche Diagnostics Gmbh | Method for preparing polypeptides with appropriate glycosilation |
US6140445A (en) * | 1998-04-17 | 2000-10-31 | Crompton Corporation | Silane functional oligomer |
ATE314485T1 (de) * | 1998-05-29 | 2006-01-15 | Genentech Inc | Zellkulturverfahren für die produktion von glycoproteinen |
US6528286B1 (en) * | 1998-05-29 | 2003-03-04 | Genentech, Inc. | Mammalian cell culture process for producing glycoproteins |
TR200504220T2 (tr) * | 1998-12-17 | 2007-04-24 | Biogen Idec Ma Inc. | Aktif limfotoksin-beta reseptör imunoglobülin şimeAktif limfotoksin-beta reseptör imunoglobülin şimerik proteinlerinin yüksek düzey ifadesi ve saflaştrik proteinlerinin yüksek düzey ifadesi ve saflaştırılması için bir yöntem.ırılması için bir yöntem. |
GB9828624D0 (en) * | 1998-12-23 | 1999-02-17 | Glaxo Group Ltd | Production of proteins |
KR100475417B1 (ko) * | 1998-12-30 | 2005-07-18 | 씨제이 주식회사 | 시알산 함량이 높은 재조합 당단백질의 제조방법 |
US7294481B1 (en) * | 1999-01-05 | 2007-11-13 | Immunex Corporation | Method for producing recombinant proteins |
EP1171615B1 (en) | 1999-04-26 | 2006-12-13 | Genentech, Inc. | Cell culture process for glycoproteins |
US6261805B1 (en) * | 1999-07-15 | 2001-07-17 | Boyce Thompson Institute For Plant Research, Inc. | Sialyiation of N-linked glycoproteins in the baculovirus expression vector system |
KR100394474B1 (ko) * | 1999-12-18 | 2003-08-09 | 동아제약 주식회사 | 동물세포에서 재조합 당단백질의 연속식 대량생산 방법 |
WO2001087922A2 (en) * | 2000-05-16 | 2001-11-22 | Lipoxen Technologies Limited | Derivatisation of proteins in aqueous solution |
WO2002002793A1 (fr) * | 2000-07-05 | 2002-01-10 | Japan As Represented By Secretary Of Osaka University | Processus de production de glycoproteine |
US20030040095A1 (en) * | 2001-03-16 | 2003-02-27 | Achille Arini | Method for the production of pharmaceutically active recombinant proteins |
US20030087372A1 (en) * | 2001-06-13 | 2003-05-08 | Genentech, Inc. | Methods of culturing animal cells and polypeptide production in animal cells |
PL376821A1 (pl) * | 2002-03-27 | 2006-01-09 | Immunex Corporation | Sposoby zwiększania produkcji polipeptydów |
US20030190710A1 (en) * | 2002-03-28 | 2003-10-09 | Devries Ruth L. | Control of glycoforms in IgG |
US6924124B1 (en) * | 2002-08-23 | 2005-08-02 | Immunex Corporation | Feeding strategies for cell culture |
US7067279B1 (en) | 2002-08-23 | 2006-06-27 | Immunex Corporation | Cell culture performance with betaine |
US6974681B1 (en) | 2002-08-23 | 2005-12-13 | Immunex Corporation | Cell culture performance with vanadate |
ES2347239T3 (es) * | 2002-12-02 | 2010-10-27 | Amgen Fremont Inc. | Anticuerpos dirigidos al factor de necrosis tumoral y usos de los mismos. |
ES2354610T5 (es) * | 2002-12-23 | 2020-09-14 | Bristol Myers Squibb Co | Mejora de la calidad del producto en procedimientos de cultivo de células de mamífero para la producción de proteína |
WO2004058800A2 (en) * | 2002-12-23 | 2004-07-15 | Bristol-Myers Squibb Company | Mammalian cell culture processes for protein production |
AU2004234377A1 (en) * | 2003-04-25 | 2004-11-11 | Immunex Corporation | Inducers of recombinant protein expression |
WO2005040377A2 (en) | 2003-10-24 | 2005-05-06 | Selexis S.A. | High efficiency gene transfer and expression in mammalian cells by a multiple transfection procedure of matrix attachment region sequences |
EP1697414A2 (en) * | 2003-12-23 | 2006-09-06 | Applied Research Systems ARS Holding N.V. | Process for the production of tumor necrosis factor-binding proteins |
EP1709185A1 (en) * | 2003-12-31 | 2006-10-11 | Samyang Genex Corporation | Method for mass production of secondary metabolites in plant cell culture by treatment of an alkanoic acid or salt thereof |
US8609370B2 (en) * | 2004-02-13 | 2013-12-17 | Glycotope Gmbh | Highly active glycoproteins-process conditions and an efficient method for their production |
US7335491B2 (en) * | 2004-08-27 | 2008-02-26 | Wyeth Research Ireland Limited | Production of anti-abeta |
TWI364458B (en) * | 2004-08-27 | 2012-05-21 | Wyeth Res Ireland Ltd | Production of tnfr-lg |
TWI384069B (zh) * | 2004-08-27 | 2013-02-01 | Pfizer Ireland Pharmaceuticals | 多胜肽之製法 |
MX2007014148A (es) * | 2005-05-19 | 2008-01-11 | Amgen Inc | Composiciones y metodos para incrementar la estabilidad de anticuerpos. |
JP2008541746A (ja) * | 2005-06-03 | 2008-11-27 | ビオヴィトルム・アクチボラゲット(プブリクト) | 新規プロセス |
KR100670105B1 (ko) | 2005-06-29 | 2007-01-17 | 주식회사 셀트리온 | 콩가수분해물의 저분자량 분획을 이용하여 시알산 함량이증가된 에리스로포이에틴을 생산하는 방법 및 그에 의하여생산된 시알산 함량이 증가된 에리스로포이에틴 |
US8470318B2 (en) | 2005-11-07 | 2013-06-25 | The Rockefeller University | Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods |
WO2008057634A2 (en) * | 2006-10-26 | 2008-05-15 | The Rockefeller University | Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods |
PL2253644T3 (pl) | 2005-12-20 | 2014-04-30 | Bristol Myers Squibb Co | Kompozycje i sposoby wytwarzania kompozycji |
AR058568A1 (es) | 2005-12-20 | 2008-02-13 | Bristol Myers Squibb Co | Metodos para producir una composicion con moleculas ctla4-ig a partir de un medio de cultivo |
US20070190057A1 (en) | 2006-01-23 | 2007-08-16 | Jian Wu | Methods for modulating mannose content of recombinant proteins |
JP5199886B2 (ja) * | 2006-01-26 | 2013-05-15 | レコファーマ アーベー | ウイルスの接着を阻害するための組成物および方法 |
EP3456351A1 (en) * | 2006-04-05 | 2019-03-20 | The Rockefeller University | Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods |
CN101541950A (zh) | 2006-07-13 | 2009-09-23 | 惠氏公司 | 糖蛋白的产生 |
AU2007294731B2 (en) | 2006-09-13 | 2014-04-17 | Abbvie Inc. | Cell culture improvements |
US8911964B2 (en) | 2006-09-13 | 2014-12-16 | Abbvie Inc. | Fed-batch method of making human anti-TNF-alpha antibody |
US20080145893A1 (en) * | 2006-09-17 | 2008-06-19 | Excellegene Sa | Method for producing a recombinant protein at high specific productivity, high batch yield and high volumetric yield by means of transient transfection |
WO2008069244A1 (ja) * | 2006-12-05 | 2008-06-12 | Kyowa Hakko Kogyo Co., Ltd. | 糖蛋白質組成物の製造方法 |
JP5175336B2 (ja) * | 2007-04-16 | 2013-04-03 | モメンタ ファーマシューティカルズ インコーポレイテッド | 細胞表面グリコシル化に関連する方法 |
TW200902708A (en) | 2007-04-23 | 2009-01-16 | Wyeth Corp | Methods of protein production using anti-senescence compounds |
US20090023186A1 (en) * | 2007-07-22 | 2009-01-22 | Excellgene Sa | Use of valproic acid for enhancing production of recombinant proteins in mammalian cells |
EP3327132A3 (en) * | 2007-08-09 | 2018-07-18 | Wyeth LLC | Use of perfusion to enhance production of fed-batch cell culture in bioreactors |
EP3760715B1 (en) * | 2008-03-06 | 2021-08-04 | Halozyme, Inc. | Large-scale production of soluble hyaluronidase |
TWI395593B (zh) | 2008-03-06 | 2013-05-11 | Halozyme Inc | 可活化的基質降解酵素之活體內暫時性控制 |
EP2283043B1 (en) * | 2008-04-07 | 2014-08-13 | Bayer HealthCare, LLC | Methods of recombinant production of glycoproteins |
US7846744B2 (en) | 2008-04-22 | 2010-12-07 | Ravetch Jeffrey V | Methods of identifying anti-inflammatory compounds |
BRPI0913475B8 (pt) | 2008-09-15 | 2019-05-07 | Genentech Inc | vetor |
NZ592097A (en) | 2008-10-20 | 2013-01-25 | Abbott Lab | Viral inactivation during purification of il-12 and il-18 antibodies |
CA2911256A1 (en) * | 2008-10-20 | 2010-12-09 | Robert K. Hickman | Isolation and purification of antibodies using protein a affinity chromatography |
CN102307993B (zh) | 2008-12-09 | 2014-06-25 | 哈洛齐梅公司 | 延长的可溶性ph20多肽及其用途 |
EP2403523A1 (en) * | 2009-03-06 | 2012-01-11 | Halozyme, Inc. | Temperature sensitive mutants of matrix metalloprotease 1 und uses thereof |
US9540426B2 (en) * | 2009-10-06 | 2017-01-10 | Bristol-Myers Squibb Company | Mammalian cell culture processes for protein production |
BR112012009828B8 (pt) | 2009-10-26 | 2022-10-25 | Hoffmann La Roche | Método para a produção de uma imunoglobulina glicosilada e seu uso |
EP3255153A1 (en) | 2009-11-17 | 2017-12-13 | E. R. Squibb & Sons, L.L.C. | Methods for enhanced protein production |
CA2782320A1 (en) * | 2009-12-02 | 2011-06-09 | Acceleron Pharma Inc. | Compositions and methods for increasing serum half-life of fc fusion proteins |
NZ601790A (en) * | 2010-02-24 | 2014-03-28 | Zymenex As | Process for production and purification of recombinant lysosomal alpha-mannosidase |
JPWO2012017925A1 (ja) | 2010-08-02 | 2013-10-03 | 協和発酵キリン株式会社 | 物質の製造方法 |
EP2686423A4 (en) | 2011-03-14 | 2015-01-28 | Nat Res Council Canada | METHOD FOR PRODUCING VIRUSES IN CELLS |
WO2012149197A2 (en) | 2011-04-27 | 2012-11-01 | Abbott Laboratories | Methods for controlling the galactosylation profile of recombinantly-expressed proteins |
MY169935A (en) | 2011-04-29 | 2019-06-18 | Biocon Biologics India Ltd | "a method for reducing heterogeneity of antibodies and a process of producing the antibodies thereof" |
US8883982B2 (en) | 2011-06-08 | 2014-11-11 | Acceleron Pharma, Inc. | Compositions and methods for increasing serum half-life |
US9067990B2 (en) | 2013-03-14 | 2015-06-30 | Abbvie, Inc. | Protein purification using displacement chromatography |
WO2013158273A1 (en) | 2012-04-20 | 2013-10-24 | Abbvie Inc. | Methods to modulate c-terminal lysine variant distribution |
US9334319B2 (en) | 2012-04-20 | 2016-05-10 | Abbvie Inc. | Low acidic species compositions |
WO2013176754A1 (en) | 2012-05-24 | 2013-11-28 | Abbvie Inc. | Novel purification of antibodies using hydrophobic interaction chromatography |
CN102839157A (zh) * | 2012-07-12 | 2012-12-26 | 扬州大学 | 稳定共表达hST3GalIV和β1-4GalT1的MDCK细胞系及构建方法和应用 |
US9512214B2 (en) | 2012-09-02 | 2016-12-06 | Abbvie, Inc. | Methods to control protein heterogeneity |
KR20150043523A (ko) | 2012-09-02 | 2015-04-22 | 애브비 인코포레이티드 | 단백질 불균일성의 제어 방법 |
NO2760138T3 (ru) | 2012-10-01 | 2018-08-04 | ||
US20140106405A1 (en) * | 2012-10-15 | 2014-04-17 | Bristol-Myers Squibb Company | Mammalian cell culture processes for protein production |
WO2014062535A1 (en) | 2012-10-15 | 2014-04-24 | Bristol-Myers Squibb Company | Mammalian cell culture processes for protein production |
SG11201507230PA (en) | 2013-03-12 | 2015-10-29 | Abbvie Inc | Human antibodies that bind human tnf-alpha and methods of preparing the same |
WO2014159579A1 (en) | 2013-03-14 | 2014-10-02 | Abbvie Inc. | MUTATED ANTI-TNFα ANTIBODIES AND METHODS OF THEIR USE |
US9017687B1 (en) | 2013-10-18 | 2015-04-28 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same using displacement chromatography |
US9217168B2 (en) | 2013-03-14 | 2015-12-22 | Momenta Pharmaceuticals, Inc. | Methods of cell culture |
WO2014151878A2 (en) | 2013-03-14 | 2014-09-25 | Abbvie Inc. | Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides |
AR095196A1 (es) | 2013-03-15 | 2015-09-30 | Regeneron Pharma | Medio de cultivo celular libre de suero |
JP6563910B2 (ja) | 2013-07-04 | 2019-08-21 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | 血清サンプル中の抗薬物抗体を検出するための干渉抑制イムノアッセイ |
BR112015032800A2 (pt) | 2013-07-06 | 2017-07-25 | Cadila Healthcare Ltd | processo para a produção de um anticorpo |
US9598667B2 (en) | 2013-10-04 | 2017-03-21 | Abbvie Inc. | Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins |
US8946395B1 (en) | 2013-10-18 | 2015-02-03 | Abbvie Inc. | Purification of proteins using hydrophobic interaction chromatography |
US9085618B2 (en) | 2013-10-18 | 2015-07-21 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same |
US9181337B2 (en) | 2013-10-18 | 2015-11-10 | Abbvie, Inc. | Modulated lysine variant species compositions and methods for producing and using the same |
WO2015073884A2 (en) | 2013-11-15 | 2015-05-21 | Abbvie, Inc. | Glycoengineered binding protein compositions |
RU2712562C2 (ru) * | 2014-02-27 | 2020-01-29 | Ф.Хоффманн-Ля Рош Аг | Модулирование клеточного роста и гликозилирования при производстве рекомбинантных гликопротеинов |
JP6652334B2 (ja) | 2014-05-31 | 2020-02-19 | Jcrファーマ株式会社 | ウリジンとn−アセチル−d−マンノサミンとを含有する培地 |
BR112016028538A2 (pt) * | 2014-06-03 | 2017-08-22 | Lupin Ltd | processo de produção de proteína glicosilada, processos de produção de proteína de fusão e anticorpo monoclonal e fragmento do mesmo, processo de produção de proteína de fusão tnfr-fc, proteína de fusão ou anticorpo monoclonal e fragmento do mesmo |
US20160130324A1 (en) | 2014-10-31 | 2016-05-12 | Shire Human Genetic Therapies, Inc. | C1 Inhibitor Fusion Proteins and Uses Thereof |
KR102007930B1 (ko) * | 2014-12-31 | 2019-08-06 | 주식회사 엘지화학 | 재조합 당단백질의 글리코실화 조절 방법 |
TW202340452A (zh) | 2015-08-04 | 2023-10-16 | 美商再生元醫藥公司 | 補充牛磺酸之細胞培養基及用法 |
MA43270A (fr) | 2015-11-19 | 2021-06-02 | Takeda Pharmaceuticals Co | Inhibiteur de la c1 estérase humaine recombinante et ses utilisations |
CN108882740A (zh) * | 2015-12-29 | 2018-11-23 | N·V·努特里奇亚 | 含有不可消化寡糖的发酵配方物 |
US20200385673A1 (en) * | 2017-11-30 | 2020-12-10 | Hoffmann-La Roche Inc. | Process for culturing mammalian cells |
BR112021008879A2 (pt) | 2018-11-13 | 2021-10-26 | Janssen Biotech, Inc. | Controle de oligometais durante a produção de anticorpos anti-cd38 |
CN114206924A (zh) | 2019-12-06 | 2022-03-18 | 瑞泽恩制药公司 | 抗vegf蛋白组合物及其制备方法 |
IL300828A (en) | 2020-08-31 | 2023-04-01 | Regeneron Pharma | Asparagine feeding strategies to improve cell culture performance and reduce asparagine sequence variants |
CN116761880A (zh) | 2021-01-20 | 2023-09-15 | 瑞泽恩制药公司 | 改进细胞培养物中的蛋白质滴度的方法 |
CA3230985A1 (en) | 2021-10-07 | 2023-04-13 | Ross BROWNE | Ph meter calibration and correction |
US20230116199A1 (en) | 2021-10-07 | 2023-04-13 | Regeneron Pharmaceuticals, Inc. | Systems and methods of ph modeling and control |
US20240010737A1 (en) | 2022-03-02 | 2024-01-11 | Regeneron Pharmaceuticals, Inc. | Manufacturing process for high titer antibody |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3926723A (en) | 1974-08-08 | 1975-12-16 | Massachusetts Inst Technology | Method of controllably releasing glucose to a cell culture medium |
JPS5938488B2 (ja) | 1979-05-07 | 1984-09-17 | 株式会社東芝 | 空気調和機 |
GB2122207B (en) * | 1982-06-21 | 1986-02-12 | Wellcome Found | Interferon production |
US4560655A (en) | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
US4724206A (en) * | 1984-02-13 | 1988-02-09 | Damon Biotech, Inc. | Protein production using hypertonic media |
GB8516415D0 (en) | 1985-06-28 | 1985-07-31 | Celltech Ltd | Culture of animal cells |
JPH0639919B2 (ja) | 1985-08-29 | 1994-05-25 | トヨタ自動車株式会社 | 過給機付き内燃機関の異常判別装置 |
GB8606386D0 (en) * | 1986-03-14 | 1986-04-23 | Celltech Ltd | Production of protein |
US4927762A (en) | 1986-04-01 | 1990-05-22 | Cell Enterprises, Inc. | Cell culture medium with antioxidant |
WO1988001643A1 (en) | 1986-08-29 | 1988-03-10 | Endotronics, Inc. | Method of culturing cells |
JPH01257492A (ja) * | 1987-03-05 | 1989-10-13 | Green Cross Corp:The | 異種蛋白質の生産増強方法 |
IL87737A (en) * | 1987-09-11 | 1993-08-18 | Genentech Inc | Method for culturing polypeptide factor dependent vertebrate recombinant cells |
JPH066054B2 (ja) | 1987-10-15 | 1994-01-26 | 帝人株式会社 | 動物細胞の培養方法 |
CA1312030C (en) * | 1987-11-18 | 1992-12-29 | Brian Maiorella | Method to increase antibody titer |
US5151359A (en) * | 1988-05-19 | 1992-09-29 | Mitsui Toatsu Chemicals Incorporated | Method for producing of human tissue type plasminogen activator |
ATE135397T1 (de) | 1988-09-23 | 1996-03-15 | Cetus Oncology Corp | Zellenzuchtmedium für erhöhtes zellenwachstum, zur erhöhung der langlebigkeit und expression der produkte |
KR0132666B1 (en) * | 1989-03-14 | 1998-04-14 | Hitachi Kk | Method for controlling cultivation conditions for animal cells |
JPH0396383A (ja) | 1989-09-08 | 1991-04-22 | Riso Kagaku Corp | 画像形成装置 |
DK0939121T4 (da) | 1989-09-12 | 2008-02-04 | Ahp Mfg B V | TNF-bindende proteiner |
US5096816A (en) * | 1990-06-05 | 1992-03-17 | Cetus Corporation | In vitro management of ammonia's effect on glycosylation of cell products through pH control |
US5122469A (en) * | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
GB9022545D0 (en) * | 1990-10-17 | 1990-11-28 | Wellcome Found | Culture medium |
GB2251249B (en) * | 1990-12-28 | 1995-06-21 | Mogam Biotech Res Inst | High-density medium for animal cell culture |
WO1993010260A1 (en) * | 1991-11-21 | 1993-05-27 | The Board Of Trustees Of The Leland Stanford Junior University | Controlling degradation of glycoprotein oligosaccharides by extracellular glycosisases |
US5447851B1 (en) * | 1992-04-02 | 1999-07-06 | Univ Texas System Board Of | Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells |
WO1994006476A1 (en) * | 1992-09-15 | 1994-03-31 | Immunex Corporation | Method of treating tnf-dependent inflammation using tumor necrosis factor antagonists |
JP3523293B2 (ja) † | 1993-07-19 | 2004-04-26 | 住友製薬株式会社 | インターフェロンの産生増強法 |
US5705364A (en) † | 1995-06-06 | 1998-01-06 | Genentech, Inc. | Mammalian cell culture process |
JP5515221B2 (ja) † | 2008-01-28 | 2014-06-11 | 日油株式会社 | ポリオキシエチレンソルビタン脂肪酸エステルの製造方法 |
-
1995
- 1995-06-06 US US08/469,348 patent/US5705364A/en not_active Expired - Lifetime
-
1996
- 1996-06-05 TW TW085106712A patent/TW426734B/zh not_active IP Right Cessation
- 1996-06-05 TW TW089111534A patent/TW516962B/zh not_active IP Right Cessation
- 1996-06-06 CA CA002220684A patent/CA2220684C/en not_active Expired - Lifetime
- 1996-06-06 TR TR97/01543T patent/TR199701543T1/xx unknown
- 1996-06-06 SK SK1670-97A patent/SK282658B6/sk not_active IP Right Cessation
- 1996-06-06 SI SI9630715T patent/SI0832189T2/sl unknown
- 1996-06-06 ES ES96918251T patent/ES2248812T5/es not_active Expired - Lifetime
- 1996-06-06 RO RO97-02262A patent/RO120267B1/ro unknown
- 1996-06-06 MY MYPI96002265A patent/MY113496A/en unknown
- 1996-06-06 CN CNB961944498A patent/CN1166772C/zh not_active Expired - Lifetime
- 1996-06-06 DE DE69637867T patent/DE69637867D1/de not_active Expired - Lifetime
- 1996-06-06 ZA ZA9604776A patent/ZA964776B/xx unknown
- 1996-06-06 SI SI9630767T patent/SI1609853T2/sl unknown
- 1996-06-06 IL IL12239896A patent/IL122398A/en not_active IP Right Cessation
- 1996-06-06 CZ CZ19973909A patent/CZ293719B6/cs not_active IP Right Cessation
- 1996-06-06 NZ NZ310202A patent/NZ310202A/en not_active IP Right Cessation
- 1996-06-06 DE DE69635076T patent/DE69635076T3/de not_active Expired - Lifetime
- 1996-06-06 KR KR1019970708954A patent/KR100496356B1/ko not_active IP Right Cessation
- 1996-06-06 EP EP05017434.1A patent/EP1609853B2/en not_active Expired - Lifetime
- 1996-06-06 EA EA199700364A patent/EA001215B1/ru not_active IP Right Cessation
- 1996-06-06 PT PT05017434T patent/PT1609853E/pt unknown
- 1996-06-06 AR ARP960103001A patent/AR004940A1/es active IP Right Grant
- 1996-06-06 DK DK05017434.1T patent/DK1609853T4/da active
- 1996-06-06 EP EP96918251A patent/EP0832189B2/en not_active Expired - Lifetime
- 1996-06-06 HU HU9900920A patent/HU226420B1/hu unknown
- 1996-06-06 UA UA97125856A patent/UA47428C2/ru unknown
- 1996-06-06 DK DK96918251T patent/DK0832189T4/da active
- 1996-06-06 BR BR9609150A patent/BR9609150A/pt not_active Application Discontinuation
- 1996-06-06 PL PL96323737A patent/PL185484B1/pl unknown
- 1996-06-06 AT AT96918251T patent/ATE302266T1/de active
- 1996-06-06 AT AT05017434T patent/ATE425245T2/de active
- 1996-06-06 AU AU60952/96A patent/AU717847B2/en not_active Expired
- 1996-06-06 WO PCT/US1996/009284 patent/WO1996039488A1/en active IP Right Grant
- 1996-06-06 GE GEAP19964011A patent/GEP20012519B/en unknown
- 1996-06-06 JP JP9501638A patent/JPH11507523A/ja not_active Withdrawn
- 1996-06-06 ES ES05017434T patent/ES2324046T5/es not_active Expired - Lifetime
- 1996-10-07 SA SA96170351A patent/SA96170351B1/ar unknown
-
1997
- 1997-12-03 BG BG102101A patent/BG63213B1/bg unknown
- 1997-12-03 IS IS4626A patent/IS2614B/is unknown
- 1997-12-05 NO NO19975674A patent/NO322276B1/no not_active IP Right Cessation
- 1997-12-05 OA OA70153A patent/OA10753A/en unknown
-
1998
- 1998-02-12 AR ARP980100640A patent/AR011439A2/es unknown
- 1998-12-23 HK HK98114966A patent/HK1017903A1/xx not_active IP Right Cessation
-
2006
- 2006-06-28 HK HK06107347.9A patent/HK1087151A1/xx not_active IP Right Cessation
-
2007
- 2007-02-28 JP JP2007050848A patent/JP4348376B2/ja not_active Expired - Lifetime
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA199700364A1 (ru) | Способ контроля силилирования протеинов, продуцируемых в культуре клеток млекопитающих | |
NO973801D0 (no) | Nye proteiner og fremgangsmåter for fremstilling av proteinene | |
ATE352630T1 (de) | Zirkuläres dna molekül mit einem abhängigen replikationsursprung, seine herstellungsverfahren und seine verwendung in der gentherapie | |
NO960111L (no) | Preparater og metoder for stimulering av vekst og differensiering av megakaryocytter | |
EP3019528A1 (en) | Improved process for production of monoclonal antibodies | |
Benya | EC collagen: biosynthesis by corneal endothelial cells and separation from type IV without pepsin treatment or denaturation | |
Kinoshita et al. | Keratin-like proteins in corneal and conjunctival epithelium are different. | |
ATE95231T1 (de) | Proteinproduktion mittels zellkultur. | |
EP0017570A1 (en) | Process for the preparation of interferon and culture medium composition used in it | |
DE69012377D1 (de) | Polypeptid und dessen Herstellung. | |
Elstow et al. | Bovine retinal angiogenesis factor is a small molecule (molecular mass less than 600). | |
HU189706B (en) | Improved process for the production of interferon | |
US11186858B1 (en) | Methods for increasing biosimilarity | |
EP0315782B1 (de) | Verfahren zur Herstellung von Proteinen | |
Ebendal | Comparative screening for ciliary neurotrophic activity in organs of the rat and chicken | |
Fireman et al. | Low Molecular Weight γ-Globulins of Urine and Plasma and their Relation to 7 S γ2-Globulin | |
RU2048521C1 (ru) | Способ получения полипептида со свойствами лимфотоксина человека | |
RU94046397A (ru) | Линия клеток млекопитающих, композиция, способы получения и очистки полипептида | |
CA2156181A1 (en) | Method for obtaining an increased production of a producing celline by using a fusion protocol | |
JP2683946B2 (ja) | 細胞培養によるタンパク質産生方法 | |
Fukuda et al. | Demonstration of cross-linked cytokeratin polypeptides in transplantable rat hepatoma cells | |
JPS62294620A (ja) | 細胞増殖抑制因子及びその調製方法 | |
SU459475A2 (ru) | Способ очистки -аспарагиназы | |
JPS63150300A (ja) | TGF−β制御糖タンパク質 | |
RU2180003C2 (ru) | Рекомбинантная плазмидная днк, обеспечивающая синтез фибробластного интерферона человека клетками дрожжей, способ ее конструирования и штамм дрожжей saccharomyces cerevisiae-продуцент фибробластного интерферона человека |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK4A | Patent expired |
Designated state(s): AM AZ BY KZ KG MD TJ TM RU |